文献速递前列腺增生与排尿功能障碍

老年医保人群中膀胱过度活动症微创治疗利用趋势

Trends in the Utilization of Minimally Invasive Therapies for Overactive Bladder Among Older Adults: A National Medicare Study.
PubMed 文献 · Urology · 2026-09-18

基于20%美国联邦医保按服务付费受益人样本,分析2015至2020年膀胱过度活动症微创治疗(BTX、PTNS、SNM)的使用趋势。调整后发病率从2015年141.2/10万升至2019年159.3/10万,相对增加13%,主要由BTX驱动(相对增加40%);2020年所有微创治疗发病率下降。66-84岁人群中衰弱程度越高,三种治疗使用率越高;85岁以上人群使用率普遍较低,与衰弱状态无关。

要点

  • 2015至2019年OAB微创治疗调整后发病率相对增加13%,BTX相对增加40%。
  • 66-84岁受益人衰弱程度越高,BTX、PTNS、SNM使用率越高。
  • 85岁及以上受益人三种微创治疗使用率普遍较低,与衰弱状态无关。

核心结论

  • 2015至2019年OAB微创治疗使用增加,主要由BTX驱动;85岁以上人群使用率低且与衰弱无关,提示该年龄段利用更多由年龄而非衰弱驱动。

研究设计与样本

  • 基于20%按服务付费联邦医保受益人样本的群体研究,纳入2015至2020年数据,使用多变量逻辑回归分析调整后发病率。
  • 共纳入5,944,458名受益人,其中39,211人(0.7%)在研究期间接受了OAB微创治疗。

主要发现

  • 调整后总体发病率从2015年141.2/10万升至2019年159.3/10万,相对增加13%。
  • BTX使用相对增加40%,是总体增长的主要驱动因素。
  • 2020年所有微创治疗发病率均下降。
  • 66-84岁人群中衰弱程度越高,三种治疗使用率越高。
  • 85岁以上人群中三种治疗使用率普遍较低,且与衰弱状态无关。

临床怎么用

  • 在66-84岁OAB患者中,衰弱评估可能有助于识别微创治疗使用倾向较高的人群。
  • 对85岁以上OAB患者,微创治疗使用率普遍较低,临床决策需综合考虑年龄因素。

局限性

  • 研究为观察性设计,无法确定影响微创治疗使用率的因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine population-based trends in utilization of minimally invasive therapies (MITs) for overactive bladder (OAB) stratified by age and frailty among Medicare beneficiaries. METHODS: This population-based study used a 20% sample of fee-for-service Medicare beneficiaries to investigate rates of utilization for MIT for OAB [onabotulinumtoxinA injections (BTX), percutaneous tibial nerve stimulation (PTNS), and sacral neuromodulation (SNM)] from 2015 to 2020. Adjusted incidence rates of each MIT were further stratified by age and frailty, measured by the Claims-based Frailty Index (CFI), using multivariable logistic regression. RESULTS: Among 5,944,458 beneficiaries, 39,211 (0.7%) underwent an MIT for OAB during the study period. Overall adjusted incidence increased from 141.2 per 100,000 in 2015-159.3 per 100,000 in 2019 (a 13% relative increase), driven largely by BTX (40% relative increase). Incidence decreased across all MITs in 2020. Among beneficiaries aged 66-84, greater levels of frailty were associated with higher use of all 3 therapies. However, this association was not observed in beneficiaries over age 85, where rates of use were uniformly low regardless of frailty status. CONCLUSION: Use of MITs for OAB increased from 2015 to 2019, mainly driven by increases in BTX. For all 3 types of MITs, greater levels of frailty were associated with increased utilization among beneficiaries <85 years, regardless of age, while rates for all 3 procedures were low regardless of frailty for beneficiaries ≥85, indicating that utilization of these procedures is driven more by age than frailty in the oldest age group. Further research is needed to determine the factors which influence MIT utilization rates.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Crow A, Wang L, Shatkin-Margolis A, et al. Trends in the Utilization of Minimally Invasive Therapies for Overactive Bladder Among Older Adults: A National Medicare Study. Urology. 2026. PMID: 42759772. doi:10.1016/j.urology.2026.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。